A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- 08 Mar 2018 Planned End Date changed from 1 Feb 2018 to 31 Aug 2018.
- 24 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated